Monitoring of minimal residual disease in patients with MLL-AF6-positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction

被引:26
|
作者
Mitterbauer, G
Zimmer, C
Pirc-Danoewinata, H
Haas, OA
Hojas, S
Schwarzinger, I
Greinix, H
Jäger, U
Lechner, K
Mannhalter, C
机构
[1] Univ Vienna, Sch Med, Dept Lab Med, Div Mol Biol, A-1090 Vienna, Austria
[2] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria
[3] Landeskrankenhaus Furstenfeld, Dept Internal Med, Furstenfeld, Austria
[4] Univ Vienna, Sch Med, Dept Lab Med, Div Hematol, A-1090 Vienna, Austria
[5] Univ Vienna, Sch Med, Dept Med 1, Bone Marrow Transplantat Unit, A-1090 Vienna, Austria
[6] Univ Vienna, Sch Med, Dept Med 1, Div Haematol, A-1090 Vienna, Austria
关键词
acute myeloid leukaemia; t(6; 11)(q27; q23); MLL-AF6; RT-PCR; minimal residual disease (MRD);
D O I
10.1046/j.1365-2141.2000.02076.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We studied 210 unselected patients with acute myeloid leukaemia (AML) for MLL abnormalities, Twenty-seven patients (13%) with rearranged MLL genes were identified by means of Southern blot analysis. An MLL-AF6 fusion transcript was detected in six patients by a reverse transcriptase polymerase chain reaction (RT-PCR) for the MLL-AF6 translocation. Sequence analysis showed fusion of MLL exon 7 as well as exon 6 (two patients) or MLL exon 6 as well as exon 5 (four patients) to AF6 exon 2. In only three patients could the t(6;11) also be identified by cytogenetic and/or fluorescence in situ hybridization (FISH) analysis. The MLL-AF6-positive patients were monitored by RT-PCR for a period of 6-33 months, Complete haematological remission (CR) was achieved in all six cases, but was short in 5/6 patients (range 2.6-8.3 months). In these five patients, the MLL-AF6 transcripts were detected in every sample tested after induction and consolidation chemotherapy. One patient received autologous bone marrow transplantation (BMT) which also did not lead to PCR negativity Intensive salvage therapy was unable to induce a second remission in the relapsed patients, One of the six MLL-AF6-positive patients achieved a molecular CR. He is still in CR at 33 months after diagnosis. Survival analysis indicates a poor prognosis in MLL-AF6-positive patients. The median event-free survival was 6.8 months, the median overall survival 15 months. Persistent PCR positivity was consistently associated with relapse. Thus, RT-PCR provides a valuable and sensitive tool for the identification of t(6;11)-positive AML and the monitoring of response to treatment in these patients. The results of RT-PCR may be useful to evaluate therapeutic procedures and to make treatment decisions, which will enable molecular remissions to be achieved and improve the clinical outcome in this group of patients.
引用
收藏
页码:622 / 628
页数:7
相关论文
共 50 条
  • [21] Minimal disease detection in patients with alveolar rhabdomyosarcoma using a reverse transcriptase polymerase chain reaction method
    Kelly, KM
    Womer, RB
    Barr, FG
    CANCER, 1996, 78 (06) : 1320 - 1327
  • [22] Normalizing complementary DNA by quantitative reverse transcriptase-polymerase chain reaction of β2-microglobulin:: Molecular monitoring of minimal residual disease in acute promyelocytic leukemia
    Degan, M
    Mazzocco, FT
    Di Francia, R
    Rossi, FM
    Pinto, A
    Gattei, V
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2000, 9 (02) : 98 - 109
  • [23] Verification of quantitative polymerase chain reaction method for monitoring minimal residual disease in chronic myeloid leukemia
    Svabek, Z. Tkalcic
    Paro, M. M. Kardum
    Horvat, M.
    Smoljanovic, I. Mandac
    Martinovic, M.
    Kristo, D. Radic
    CLINICA CHIMICA ACTA, 2024, 558
  • [24] Postinduction Minimal Residual Disease Monitoring by Polymerase Chain Reaction in Children With Acute Lymphoblastic Leukemia
    Paganin, Maddalena
    Fabbri, Giulia
    Conter, Valentino
    Barisone, Elena
    Polato, Katia
    Cazzaniga, Giovanni
    Giraldi, Eugenia
    Fagioli, Franca
    Arico, Maurizio
    Valsecchi, Maria Grazia
    Basso, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (31) : 3553 - +
  • [25] Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction
    Kuroda, T
    Saeki, M
    Nakano, M
    Mizutani, S
    JOURNAL OF PEDIATRIC SURGERY, 1997, 32 (01) : 69 - 72
  • [26] Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies
    Ommen, Hans Beier
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (01) : 3 - 16
  • [27] Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias
    Krauter, J
    Görlich, K
    Ottmann, O
    Lübbert, M
    Döhner, H
    Heit, W
    Kanz, L
    Ganser, A
    Heil, G
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) : 4413 - 4422
  • [28] Detection of HuD transcripts by means of reverse transcriptase and polymerase chain reaction:: implications for the detection of minimal residual disease in patients with small cell lung cancer
    Torà, M
    Barberá, VM
    Real, FX
    CANCER LETTERS, 2000, 161 (02) : 157 - 164
  • [29] Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations
    W-C Chou
    J-L Tang
    S-J Wu
    W Tsay
    M Yao
    S-Y Huang
    K-C Huang
    C-Y Chen
    C-F Huang
    H-F Tien
    Leukemia, 2007, 21 : 998 - 1004
  • [30] Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations
    Chou, W-C
    Tang, J-L
    Wu, S-J
    Tsay, W.
    Yao, M.
    Huang, S-Y
    Huang, K-C
    Chen, C-Y
    Huang, C-F
    Tien, H-F
    LEUKEMIA, 2007, 21 (05) : 998 - 1004